Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to survivors of breast cancer, as a ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies. Quest Diagnostics has announced the launch of a novel ...
Flatiron Health and Exact Sciences collaborate to use Flatiron's platform for rapid data analysis with the Oncodetect MRD test. The study involves 1350 patients in community settings, focusing on ...
Flatiron and Exact Sciences' partnership aims to integrate MRD testing into community oncology practices through a large-scale observational study. Community oncologists face barriers like ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading ...
Qiagen N.V. (NYSE:QGEN) has announced two strategic partnerships designed to revolutionize minimal residual disease (MRD) testing in oncology, further cementing its leadership in precision diagnostics ...
NEW YORK--(BUSINESS WIRE)-- Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results